Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases

Andrade, Fernanda; Rafael, Diana; Videira, Mafalda; Ferreira, Domingos; Sosnik, Alejandro; Sarmento, Bruno

doi:10.1016/j.addr.2013.07.020

Cited by 196 publications

(100 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…50 The treatment of infections caused by intracellular pathogens and strains with drug resistance is more complex using antibiotics 51 because of antibiotics' poor membrane transport. Drugs of average size thus have little effect on intracellular microbes.…”

Section: Acting As Good Carriers Of Antibioticsmentioning

confidence: 99%

The antimicrobial activity of nanoparticles: present situation and prospects for the future

Wang¹,

Hu²,

Shao³

2017

IJN

2,715

1,792

View full text Add to dashboard Cite

Nanoparticles (NPs) are increasingly used to target bacteria as an alternative to antibiotics. Nanotechnology may be particularly advantageous in treating bacterial infections. Examples include the utilization of NPs in antibacterial coatings for implantable devices and medicinal materials to prevent infection and promote wound healing, in antibiotic delivery systems to treat disease, in bacterial detection systems to generate microbial diagnostics, and in antibacterial vaccines to control bacterial infections. The antibacterial mechanisms of NPs are poorly understood, but the currently accepted mechanisms include oxidative stress induction, metal ion release, and non-oxidative mechanisms. The multiple simultaneous mechanisms of action against microbes would require multiple simultaneous gene mutations in the same bacterial cell for antibacterial resistance to develop; therefore, it is difficult for bacterial cells to become resistant to NPs. In this review, we discuss the antibacterial mechanisms of NPs against bacteria and the factors that are involved. The limitations of current research are also discussed.

show abstract

Section: Acting As Good Carriers Of Antibioticsmentioning

confidence: 99%

The antimicrobial activity of nanoparticles: present situation and prospects for the future

Wang¹,

Hu²,

Shao³

2017

IJN

2,715

1,792

View full text Add to dashboard Cite

show abstract

“…At the moment, nanotechnology-based drug delivery systems emerged as a promising approach to circumvent the limitations of conventional drugs to assess the safety, quality, and efficacy. 70 Therefore, in the near future, nanotechnology could play a key role against MDR clinical pathogens.…”

Section: Multidrug Resistance and Antimicrobial Profile (Amp)mentioning

confidence: 99%

Synthesized zinc peroxide nanoparticles (ZnO<sub>2</sub>-NPs): a novel antimicrobial, anti-elastase, anti-keratinase, and anti-inflammatory approach toward polymicrobial burn wounds

Ali¹,

Morsy²,

El-Zawawy³

et al. 2017

IJN

116

View full text Add to dashboard Cite

Increasing of multidrug resistance (MDR) remains an intractable challenge for burn patients. Innovative nanomaterials are also in high demand for the development of new antimicrobial biomaterials that inevitably have opened new therapeutic horizons in medical approaches and lead to many efforts for synthesizing new metal oxide nanoparticles (NPs) for better control of the MDR associated with the polymicrobial burn wounds. Recently, it seems that metal oxides can truly be considered as highly efficient inorganic agents with antimicrobial properties. In this study, zinc peroxide NPs (ZnO 2 -NPs) were synthesized using the co-precipitation method. Synthesized ZnO 2 -NPs were characterized by X-ray diffraction, Fourier transformed infrared, transmission electron microscopy, thermogravimetric analysis, differential scanning calorimetry, and ultraviolet-visible spectroscopy. The characterization techniques revealed synthesis of the pure phase of non-agglomerated ZnO 2 -NPs having sizes in the range of 15–25 nm with a transition temperature of 211°C. Antimicrobial activity of ZnO 2 -NPs was determined against MDR Pseudomonas aeruginosa (PA) and Aspergillus niger (AN) strains isolated from burn wound infections. Both strains, PA6 and AN4, were found to be more susceptible strains to ZnO 2 -NPs. In addition, a significant decrease in elastase and keratinase activities was recorded with increased concentrations of ZnO 2 -NPs until 200 µg/mL. ZnO 2 -NPs revealed a significant anti-inflammatory activity against PA6 and AN4 strains as demonstrated by membrane stabilization, albumin denaturation, and proteinase inhibition. Moreover, the results of in vivo histopathology assessment confirmed the potential role of ZnO 2 -NPs in the improvement of skin wound healing in the experimental animal models. Clearly, the synthesized ZnO 2 -NPs have demonstrated a competitive capability as antimicrobial, anti-elastase, anti-keratinase, and anti-inflammatory candidates, suggesting that the ZnO 2 -NPs are promising metal oxides that are potentially valued for biomedical applications.

show abstract

“…In recent years, the advances in nanotechnology have offered unprecedent opportunities to advance the treatment of various diseases, including cancer. [2][3][4][5][6][7] The application of nanotechnology in cancer therapy, herein referred as cancer nanomedicines, have received wide spread attention due to the unique physicochemical properties of the nanoparticles with the ability to deliver different therapeutics (e.g., chemotherapeutics and biologics), altering their pharmacokinetic profiles, augmenting their accumulation in the tumors and reducing their toxicity profiles. [8][9][10][11] Nanomedicines aim to improve the balance between therapeutic efficacy and systemic toxicity of conventional chemotherapeutic agents, which lack of specificity, thereby enhancing the therapeutic index of the anticancer drugs.…”

Section: Introductionmentioning

confidence: 99%

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Balasubramanian

Liu

Hirvonen

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

Explosive growth of nanomedicines continues to significantly impact the therapeutic strategies for effective cancer treatment. Despite the significant progress in the development of advanced nanomedicines, successful clinical translation remains challenging. As cancer nanomedicine is a multidisciplinary field, the fundamental problem is that the knowledge gaps stem from different vantage points in the understanding of cancer nanomedicines. The complexities and heterogenecity of both nanomedicines and cancer are further demanding the integration of highly diverse expertise to develop clinically translatable cancer nanomedicines. This progress report aims to discuss the current understanding of cancer nanomedicines between different research areas in terms of nanoparticle engineering, formulation, tumor patho-physiology and clinical medicine, as well as to identify the knowledge gaps lying at the interface between the different fields of research in nanomedicine. Here we also highlight for the necessity to harmonize the multidisciplinary effort in the research of nanomedicines in order to bridge the knowledge and to advance the full understanding in cancer nanomedicines. A paradigm shift is needed in the strategic development of disease specific nanomedicines in order to foster the successful translation into clinic of future cancer nanomedicines.

show abstract

Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases

Cited by 196 publications

References 107 publications

The antimicrobial activity of nanoparticles: present situation and prospects for the future

The antimicrobial activity of nanoparticles: present situation and prospects for the future

Synthesized zinc peroxide nanoparticles (ZnO<sub>2</sub>-NPs): a novel antimicrobial, anti-elastase, anti-keratinase, and anti-inflammatory approach toward polymicrobial burn wounds

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Contact Info

Product

Resources

About